Abstract
The authors recruited 19 nonambulant patients with Guillain-Barré syndrome into a pilot, double-blind, randomized, placebo-controlled safety trial of interferon beta 1a (IFN[beta]-1a) (Rebif). Participants received IFN[beta]-1a or placebo subcutaneously three times weekly, 22 microg for the first week and then 44 microg for up to 24 weeks, in addition to IV immunoglobulin (IVIg). IFN[beta] did not have any unexpected interaction with IVIg and there was no significant difference in rate of improvement.
Original language | English |
---|---|
Pages (from-to) | 1282-4 |
Number of pages | 3 |
Journal | Neurology |
Volume | 61 |
Issue number | 9 |
Publication status | Published - 1 Jan 2003 |